妥瑞症（TS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計到 2025 年，妥瑞症市場價值將達到 21.4 億美元（800 萬美元），到 2035 年將達到 29.2 億美元，年複合成長率為 4.1%。
• 受管道建設和治療滲透率提高的推動，預計短期成長將更加強勁（到 2030 年複合年成長率為 6-7%）。
• 兒童患者群體占我們收入的大部分（超過 65%），這反映了年輕一代較高的診斷率和治療率。
• 總體而言，妥瑞症(TS) 的治療領域呈現出穩步市場擴張的特點，這得益於人們對該疾病的認知不斷提高、診斷技術的進步以及治療方法的不斷創新。

妥瑞症（TS）概述

妥瑞症（TS）是一種神經發育障礙，其特徵為18歲前發病，並伴隨多種運動性抽動和至少一種發聲性抽動，且持續時間超過一年。此疾病與皮質紋狀體-丘腦-皮質（CSTC）環路功能障礙有關，主要由多巴胺失調引起。

抽動症（TS）屬於抽動症頻譜，該譜系還包括暫時性抽動症和持續性運動及發聲抽動症。臨床上，TS 的病程呈現反覆發作和緩解的模式，症狀嚴重程度通常在青春期早期達到高峰。

這種疾病經常與神經行為共病同時發生，特別是注意力不足/過動症（ADHD）和強迫症（OCD），大大增加了患者的負擔。

目前，尚無針對抽動症（TS）的疾病修正治療。治療以症狀緩解為主，綜合行為介入療法（CBIT）是首選治療方案。對於中度至重度抽動症患者，如果抽動嚴重影響其生活品質，則會採用藥物治療（例如α2腎上腺素受體促效劑、多巴胺拮抗劑和VMAT2抑制劑）。

主要亮點

• TS主要影響兒童，大多數確診病例發生在兒童和青少年時期。在美國，2025年TS確診患者（兒童和青少年）人數估計為159,313人，預計到2035年將增加到168,631人。
• 確診的成人病例數仍然非常低，預計將從 2025 年的 15,815 例增加到 2035 年的 17,008 例，這反映了兒童患者（約佔確診病例的 90%）的壓倒性趨勢。
• 在預測期內，兒童和成人族群中 TS 的診斷數量預計將穩定增加。
• 儘管診斷率正在上升，但仍有相當一部分患者，特別是那些症狀輕微的患者，未得到診斷和治療，這表明存在巨大的未滿足需求。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Emalex Biosciences Inc.
• Noema Pharma AG
• Neurothera Labs Inc.
• Asarina Pharma

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前療法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及關鍵意見領袖的見解
• 新興療法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Tourette Syndrome (TS) Market Outlook

Thelansis's "Tourette Syndrome (TS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Tourette Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Tourette Syndrome (TS) Overview

Tourette syndrome (TS) is a neurodevelopmental disorder characterized by the presence of multiple motor tics and at least one vocal (phonic) tic persisting for more than one year, with onset before 18 years of age. The condition is associated with dysfunction in the cortico-striato-thalamo-cortical (CSTC) circuitry, primarily driven by dopamine dysregulation.

TS belongs to the spectrum of tic disorders, which also includes Provisional Tic Disorder and Persistent Motor or Vocal Tic Disorder. Clinically, TS follows a waxing and waning course, with symptom severity typically peaking during early adolescence.

The disorder is frequently associated with neurobehavioral comorbidities, particularly attention-deficit/hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), significantly increasing disease burden.

Currently, there are no disease-modifying therapies for TS. Treatment is symptom-driven, with Comprehensive Behavioral Intervention for Tics (CBIT) as the first-line approach. Pharmacological therapies-including alpha-2 adrenergic agonists, dopamine antagonists, and VMAT2 inhibitors-are used in moderate-to-severe cases where tics significantly impact quality of life.

Key Highlights

• The TS patient population is predominantly pediatric, with children and adolescents accounting for the majority of diagnosed cases. In the United States, the diagnosed TS population (children and adolescents) is estimated at 159,313 in 2025, increasing to 168,631 by 2035.
• The adult diagnosed population remains significantly smaller, projected to grow from 15,815 in 2025 to 17,008 by 2035, reflecting a strong pediatric skew (~90% of total diagnosed cases).
• Diagnosed TS cases are expected to grow steadily across both pediatric and adult populations over the forecast period.
• Despite increasing diagnosis rates, a significant proportion of patients-particularly those with mild symptoms-remain undiagnosed or untreated, indicating a substantial unmet need.

Market Overview

• The Tourette syndrome treatment market was valued at $2.14 billion in 2025 (8MM) and is projected to reach $2.92 billion by 2035, growing at a CAGR of 4.1%.
• Short-term growth is expected to be stronger (6-7% CAGR through 2030), driven by pipeline advancements and improved treatment uptake.
• The pediatric population contributes the majority of revenue (65%+ share), reflecting higher diagnosis and treatment rates in younger patients.
• Overall, the TS treatment landscape is characterized by steady market expansion, driven by increasing awareness, improved diagnosis, and incremental therapeutic innovation.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Emalex Biosciences Inc.
• Noema Pharma AG
• Neurothera Labs Inc.
• Asarina Pharma

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)